Protagonist Therapeutics, Inc.
PTGX
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.4B
$145.72
▼ -2.07%
P/E
119.63
Mkt Cap
$9.4B
52-Wk Range
$54.50–$160.81
52-Week Range
$54.50 - $160.81
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 159.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary peptide drug discovery and development platform enabling oral and injectable delivery
- Strategic partnership with Janssen Biotech providing resources, expertise, and commercialization support
- Differentiated mechanism of action targeting specific integrins and hepcidin pathways with fewer side effects
Bear Case
2 risks
- Above-average volatility (beta 1.8).
- Premium valuation to Biotech & Therapeutics peers
Growth
Stable outlook
Advancement of rusfertide through Phase II trials for multiple blood disorder indications with large addressable markets
Value
Premium valuation to Biotech & Therapeutics peers
Momentum
Hot
+48.6% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PTGX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of $2.29 vs $2.27 consensus (+0.9% surprise). Revenue of $213.5M vs $212.0M expected (+0.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+0.9%
Revenue trend · last 8Q
—
+184%
-89%
+33%
+1%
-96%
+99%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$4.7M
$170.6M
$28.3M
$5.5M
$4.7M
$7.4M
$56.4M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
12 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barclays · Sep 1, 2026
vs Industry
How PTGX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related